OR WAIT null SECS
Agreement provides pharma firms with an RWD and commercialization solution
Eversana, who offers global commercial services to the life sciences industry, and Thread, a technology and service provider that enables decentralized clinical trials (DCTs), have reached a combined deal to give pharma companies a comprehensive and simultaneous view of clinical research participants.
Specifics surrounding the new solution include combining Eversana’s integrated commercial services, electronic medical record (EMR) data, and real-world evidence (RWD)-driven recruitment knowledge with Thread’s DCT platform to collect and link patient-generated and secondary regulatory-grade RWD. Operating under a single platform, the offering allows for continuous active, passive, retrospective and prospective data collection, while keeping patient consent and identity security in mind. Data linkages will be performed using technology from computer software company Datavant.
The involved parties note that essentially, the combined offering supports the capture and curation of clinical and RWD across the entire spectrum of clinical research and care.
“Putting all available real-world data to work is imperative to optimize the development of new treatments and our understanding of marketed therapies,” says John Reites, CEO of Thread. “By combining the power of Thread’s technology platform with Eversana's rich, diverse data sets, clinical studies can be more efficient, comprehensive and inclusive, providing researchers with a totality of evidence to inform their research.”